SDB-001 - Revision history

Adm1n at 11:32, 14 April 2015

2015-04-14T11:32:20Z

Adm1n at 11:26, 15 February 2015

2015-02-15T11:26:20Z

Adm1n at 02:30, 15 February 2015

2015-02-15T02:30:37Z

Adm1n: Created page with "'''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the cannabinoid receptors. It had never previousl..."

2015-02-15T02:30:14Z

Created page with "'''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the cannabinoid receptors. It had never previousl..."

New page

'''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the [[cannabinoid receptors]]. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in [[synthetic cannabis]] smoking blends, along with a related compound [[APINACA]] (sold as "AKB48"). Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position. Pharmacological testing determined SDB-001 to have an IC50 of 175nM at CB1, only slightly less potent than JWH-018 which had an IC50 of 169nM, but over four times more tightly binding than AKB48, which had an IC50 of 824nM. The first published synthesis and pharmacological evaluation of SDB-001 revealed that it acts as a full agonist at [[CB1]] (EC50 = 34 nM) and [[CB2 receptors]] (EC50 = 29 nM). Furthermore, SDB-001 possesses cannabis-like effects in rats, and appears to be less potent than [[JWH-018]] but more potent than [[THC]].

==See also==

* [[AB-001]]
* [[QUCHIC]]
* [[JWH-018]]
* [[SDB-006]]
* [[STS-135 (drug)]]

← Older revision		Revision as of 11:32, 14 April 2015
Line 1:		Line 1:
−	'''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the [[cannabinoid receptors]]. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis. smoking blends, along with a related compound [[APINACA]] (sold as "AKB48"). Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position. Pharmacological testing determined SDB-001 to have an IC50 of 175nM at CB1, only slightly less potent than JWH-018 which had an IC50 of 169nM, but over four times more tightly binding than AKB48, which had an IC50 of 824nM. The first published synthesis and pharmacological evaluation of SDB-001 revealed that it acts as a full agonist at [[CB1]] (EC50 = 34 nM) and [[CB2 receptor]]s (EC50 = 29 nM). Furthermore, SDB-001 possesses cannabis-like effects in rats, and appears to be less potent than [[JWH-018]] but more potent than [[THC]].	+	'''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the cannabinoid receptors. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis. smoking blends, along with a related compound [[APINACA]] (sold as "AKB48"). Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position. Pharmacological testing determined SDB-001 to have an IC50 of 175nM at CB1, only slightly less potent than JWH-018 which had an IC50 of 169nM, but over four times more tightly binding than AKB48, which had an IC50 of 824nM. The first published synthesis and pharmacological evaluation of SDB-001 revealed that it acts as a full agonist at [[CB1]] (EC50 = 34 nM) and [[CB2 receptor]]s (EC50 = 29 nM). Furthermore, SDB-001 possesses cannabis-like effects in rats, and appears to be less potent than [[JWH-018]] but more potent than [[THC]].

← Older revision		Revision as of 11:26, 15 February 2015
Line 1:		Line 1:
−	'''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the [[cannabinoid receptors]]. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in [[synthetic cannabis]] smoking blends, along with a related compound [[APINACA]] (sold as "AKB48"). Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position. Pharmacological testing determined SDB-001 to have an IC50 of 175nM at CB1, only slightly less potent than JWH-018 which had an IC50 of 169nM, but over four times more tightly binding than AKB48, which had an IC50 of 824nM. The first published synthesis and pharmacological evaluation of SDB-001 revealed that it acts as a full agonist at [[CB1]] (EC50 = 34 nM) and [[CB2 receptor]]s (EC50 = 29 nM). Furthermore, SDB-001 possesses cannabis-like effects in rats, and appears to be less potent than [[JWH-018]] but more potent than [[THC]].	+	'''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the [[cannabinoid receptors]]. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis. smoking blends, along with a related compound [[APINACA]] (sold as "AKB48"). Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position. Pharmacological testing determined SDB-001 to have an IC50 of 175nM at CB1, only slightly less potent than JWH-018 which had an IC50 of 169nM, but over four times more tightly binding than AKB48, which had an IC50 of 824nM. The first published synthesis and pharmacological evaluation of SDB-001 revealed that it acts as a full agonist at [[CB1]] (EC50 = 34 nM) and [[CB2 receptor]]s (EC50 = 29 nM). Furthermore, SDB-001 possesses cannabis-like effects in rats, and appears to be less potent than [[JWH-018]] but more potent than [[THC]].

← Older revision		Revision as of 02:30, 15 February 2015
Line 1:		Line 1:
−	'''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the [[cannabinoid receptors]]. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in [[synthetic cannabis]] smoking blends, along with a related compound [[APINACA]] (sold as "AKB48"). Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position. Pharmacological testing determined SDB-001 to have an IC50 of 175nM at CB1, only slightly less potent than JWH-018 which had an IC50 of 169nM, but over four times more tightly binding than AKB48, which had an IC50 of 824nM. The first published synthesis and pharmacological evaluation of SDB-001 revealed that it acts as a full agonist at [[CB1]] (EC50 = 34 nM) and [[CB2 ~~receptors~~]] (EC50 = 29 nM). Furthermore, SDB-001 possesses cannabis-like effects in rats, and appears to be less potent than [[JWH-018]] but more potent than [[THC]].	+	'''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the [[cannabinoid receptors]]. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in [[synthetic cannabis]] smoking blends, along with a related compound [[APINACA]] (sold as "AKB48"). Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position. Pharmacological testing determined SDB-001 to have an IC50 of 175nM at CB1, only slightly less potent than JWH-018 which had an IC50 of 169nM, but over four times more tightly binding than AKB48, which had an IC50 of 824nM. The first published synthesis and pharmacological evaluation of SDB-001 revealed that it acts as a full agonist at [[CB1]] (EC50 = 34 nM) and [[CB2 receptor]]s (EC50 = 29 nM). Furthermore, SDB-001 possesses cannabis-like effects in rats, and appears to be less potent than [[JWH-018]] but more potent than [[THC]].